On Thursday, Shares of ABIOMED, Inc. (NASDAQ:ABMD), gained 5.77% to $104.08.
Abiomed, declared that Michael R. Minogue, Chairman, President and CEO, presented at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 at 2:55 p.m. ET. The conference will be held at the Grand Hyatt New York in New York, NY.
ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
Shares of Columbia Pipeline Partners LP (NYSE:CPPL), inclined 1.42% to $16.40, during its last trading session.
Alerian declared that following the close of business on Friday, September 18, Boardwalk Pipeline Partners LP (BWP), Columbia Pipeline Partners LP (CPPL), and Vanguard Natural Resources LLC (VNR) will be added to the Alerian MLP Index (AMZ) and the Alerian MLP Equal Weight Index (CME:AMZE).
Boardwalk Pipeline Partners provides transportation, storage, gathering and processing of natural gas and liquids. Columbia Pipeline Partners owns, operates, and develops natural gas pipelines, storage, and related midstream assets. Vanguard Natural Resources focuses on the acquisition, production, and development of oil and natural gas properties.
Hi-Crush Partners LP (HCLP), Linn Energy LLC (LINE), and Memorial Production Partners LP (MEMP) will be removed from the two indices following the close of business on September 18.
Columbia Pipeline Partners LP, through its interests in CPG OpCo LP, engages in the natural gas transmission and storage business. It owns, operates, and develops a portfolio of pipelines, storage, and related midstream assets. The company owns about 15,000 miles of interstate pipelines extending from New York to the Gulf of Mexico and underground natural gas storage systems, in addition to related gathering and processing assets.
At the end of Thursday’s trade, Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX), gained 1.18% to $54.93.
AbbVie (ABBV), declared the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy contrast to placebo. The trial was conducted in women with heavy menstrual bleeding (HMB) associated with uterine fibroids. Preliminary results showed that all of the elagolix treatment arms, with and without add-back therapy, reduced heavy menstrual bleeding as contrast to placebo (p
Uterine fibroids (also called leiomyomas or myomas) are noncancerous muscle tissue tumors of the uterus.1 Fibroids are most common in women aged 30-40 years but can occur at any age.1 They can range in size from nearly undetectable to bulky masses that can distort the uterus.2 Fibroids can be asymptomatic but in some women cause symptoms such as: longer, more frequent, or heavy menstrual bleeding; menstrual pain; vaginal bleeding at time other than menstruation; pain in the abdomen or lower back; pain during sex; difficulty urinating; frequent urination; constipation or rectal pain.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome
Finally, JinkoSolar Holding Co., Ltd. (NYSE:JKS), ended its last trade with 2.32% gain, and closed at $23.85.
JinkoSolar Holding Co., declared that JinkoSolar Power Co., Ltd. (“Jinko Power”), a partner of the Company, has signed a line of credit of up to RMB10 billion planned agreement with the Industrial and Commercial Bank of China (“ICBC”) Jiangxi Provincial branch.
According to the terms of the agreement, ICBC Jiangxi Provincial branch will provide Jinko Power line of credit of up to RMB10 billion within three years. The financial instruments will comprise but are not limited to working capital loans, supply chain financing loans, and project loans. The final amount drawn will depend on Jinko Power’s projects financing needs.
JinkoSolar Holding Co., Ltd., together with its auxiliaries, engages in the design, development, production, and marketing of photovoltaic products in the People’s Republic of China and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
